5 cash-hungry biotechs crowd into Nasdaq in search of a $600M-plus windfall
The queue to get into Nasdaq just got a lot longer.
On Friday after the markets closed 5 more biotech’s tossed their S-1s into the mix, marking at least 22 IPO pitches for the year to date. That falls in line next to the 20 biotechs that had gone public by this time last year — which marked another busy year for public market debuts and the cash they spin for R&D work.
We broke it out on a case-by-case basis:
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
